Abstract
BackgroundCanakinumab (CAN), a selective, human anti-interleukin (IL)−1β mAb, has demonstrated efficacy and safety in patients (pts) with colchicine-resistant familial Mediterranean fever (crFMF), TNF receptor-associated periodic syndrome (TRAPS), and hyper-IgD syndrome...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have